Log in to search using one of your social media accounts:

 

Florida boy diagnosed with brain tumor after concussion
Logan Silva, seven, was diagnosed with medulloblastoma, a fast-growing brain tumor. After getting a concussion, the boy from Florida suffered extreme headaches which turned out to be a tumor. (Source: the Mail online | Health)
Source: the Mail online | Health - November 2, 2017 Category: Consumer Health News Source Type: news

New study discovers faulty genes underlying brain tumours
A new in-depth study funded by Cancer Research UK has shown that medulloblastoma brain tumours have faulty genes underlying the disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 26, 2017 Category: Pharmaceuticals Source Type: news

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors
(St. Jude Children's Research Hospital) An international consortium co-led by St. Jude Children's Research Hospital completed a landmark study of most common pediatric brain tumor, revealing new cancer genes, laying the foundation to expand precision medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2017 Category: Cancer & Oncology Source Type: news

Researchers identify a key controller of biological machinery in cell's 'antenna'
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital discovery of a regulatory enzyme working at the primary cilium could lead to treatments for the brain tumor medulloblastoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2017 Category: Cancer & Oncology Source Type: news

PID1 gene enhances effectiveness of chemotherapy on brain cancer cells
The gene PID1 enhances killing of medulloblastoma and glioblastoma cells, investigators have found. Medulloblastoma is the most commonly occurring malignant primary brain tumor in children; glioblastoma is the most commonly occurring malignant primary brain tumor in adults. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 11, 2017 Category: Science Source Type: news

PID1 gene enhances effectiveness of chemotherapy on brain cancer cells
(Children's Hospital Los Angeles) Investigators at The Saban Research Institute of Children's Hospital Los Angeles have found that the gene PID1 enhances killing of medulloblastoma and glioblastoma cells. Medulloblastoma is the most commonly occurring malignant primary brain tumor in children; glioblastoma is the most commonly occurring malignant primary brain tumor in adults. Results of this study will be published in Scientific Reports on April 11. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2017 Category: Global & Universal Source Type: news

Caution needed for drugs in development for most common malignant pediatric brain tumor
(St. Jude Children's Research Hospital) Researchers at St. Jude Children's Research Hospital have studied how a crucial cancer-related protein plays a role in one of the most aggressive forms of medulloblastoma, the most common malignant brain tumor of childhood. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2017 Category: Cancer & Oncology Source Type: news

Molecular'on switch' could point to treatments for pediatric brain tumor
Massachusetts General Hospital researchers have identified a mechanism that controls the expression of genes regulating the growth of the most aggressive form of medulloblastoma, the most common pediatric brain tumor. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 24, 2017 Category: Science Source Type: news

Molecular 'on switch' could point to treatments for pediatric brain tumor
(Massachusetts General Hospital) Massachusetts General Hospital researchers have identified a mechanism that controls the expression of genes regulating the growth of the most aggressive form of medulloblastoma, the most common pediatric brain tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 24, 2017 Category: Cancer & Oncology Source Type: news

Husband-wife team at Children ’s Mercy declares war on brain cancer
Children ’s Mercy Chief Scientific Officer Tom Curran and Assistant Professor of Pediatrics Jessie Ng have a long history. The husband-and-wife duo have worked together for more than a decade, evaluating pediatric brain cancer treatments. Before Curran joined Children’s Mercy in February 2016, Ng worked for Curran at the Children’s Hospital of Philadelphia, where he led translational childhood cancer research. Among numerous projects, he and Ng tested a new treatment for medulloblastoma, the… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 17, 2017 Category: American Health Authors: Elise Reuter Source Type: news

ASTRO releases updated APBI guide
The American Society for Radiation Oncology (ASTRO) has released an updated...Read more on AuntMinnie.comRelated Reading: ASTRO: PET predicts outcomes in vulvar cancer patients ASTRO: Radiation boost cuts local recurrence in DCIS patients ASTRO: Negative PET/CT doesn't always mean dormant NSCLC ASTRO: Prostate cancer has 3 molecular subtypes ASTRO: OK to cut RT dose for primary medulloblastoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2016 Category: Radiology Source Type: news

Genetic signaling pathway blocks formation of a cancer in the cerebellum
A signaling pathway has the potential to block a type of cancer in the cerebellum, suggests new research. The work is focused on brain tumor formation in animal models of medulloblastoma, the most common malignant brain tumor diagnosed in children. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 8, 2016 Category: Science Source Type: news

Adding Chemotherapy in Medulloblastoma Linked With Improved Survival
A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation for adults with medulloblastoma improves survival. (Source: CancerNetwork)
Source: CancerNetwork - November 4, 2016 Category: Cancer & Oncology Authors: Benjamin Kann, MD Tags: Brain Tumors Radiation Oncology Source Type: news

Could targeting a gene linked to microcephaly lead to a better brain cancer treatment?
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers report preclinical findings showing promise for targeting a gene linked to microcephaly in infants as a treatment for medulloblastoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2016 Category: Cancer & Oncology Source Type: news

Shortened RT works for low-risk prostate cancer patients
A shortened, higher-dose radiation therapy (RT) protocol is safe for low-risk...Read more on AuntMinnie.comRelated Reading: ASTRO: PET predicts outcomes in vulvar cancer patients ASTRO: Radiation boost cuts local recurrence in DCIS patients ASTRO: Negative PET/CT doesn't always mean dormant NSCLC ASTRO: Prostate cancer has 3 molecular subtypes ASTRO: OK to cut RT dose for primary medulloblastoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 4, 2016 Category: Radiology Source Type: news

Markers Could Improve Treatment Stratification for Pediatric Medulloblastoma
The use of an intensified treatment regimen to treat metastatic medulloblastoma in children and adolescents conferred an overall favorable survival, according to the results of a recent study. However, patients within varying subgroups and with certain biologic parameters did not have uniform outcomes. (Source: CancerNetwork)
Source: CancerNetwork - October 3, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Brain Tumors Pediatric Cancers Source Type: news

ASTRO: OK to cut RT dose for primary medulloblastoma
Reduced doses for radiation therapy (RT) for pediatric medulloblastoma at the...Read more on AuntMinnie.comRelated Reading: Pediatric proton therapy treatments on the rise SNMMI: PET, MRI may predict pediatric brain tumor outcomes ASTRO: Study lauds proton therapy Imaging advances therapy assessment Proton therapy offers hope to pediatric brain cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2016 Category: Radiology Source Type: news

Medulloblastoma patients should receive both chemotherapy and radiation post-surgery
The addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival, new research demonstrates. Medulloblastoma (MB) is the most common brain tumor in children, but is relatively rare in adults. Chemotherapy use in adult MB is largely based on pediatric outcomes, and its effectiveness has been unclear. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 26, 2016 Category: Science Source Type: news

DelMar, Accurexa ink deal for chemotherapy combo
DelMar Pharmaceuticals and Accurexa  said today that they inked a deal to collaborate on a combination chemotherapy for local treatment of brain cancer. The agreement calls for DelMar to supply the drug dianhydrogalactitol (VAL-083) as part of a combination with another chemotherapeutic, either temozolomide or carmustine, for local delivery to the tumor via Accurexa’s ACX-31 implantable polymer wafer. DelMar said its drug proved successful in more than 40 clinical trials sponsored by the U.S. National Cancer Institute, winning orphan drug designation as a treatment for gliomas, medulloblastoma and ovarian c...
Source: Mass Device - September 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Oncology Pharmaceuticals Research & Development Accurexa Inc. DelMar Pharmaceuticals Source Type: news

Deferring Postoperative RT for Pediatric Medulloblastoma Affected Survival
The deferral of postoperative radiotherapy is increasing among children with medulloblastoma, and this deferral of treatment was associated with worse survival. (Source: CancerNetwork)
Source: CancerNetwork - August 26, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Brain Tumors News Source Type: news

Brain Function Differs By Medulloblastoma Subtype
Patients with different molecular subtypes of medulloblastoma, a common type of childhood brain tumor, have varying decline in brain function following radiation therapy for their disease. (Source: CancerNetwork)
Source: CancerNetwork - August 10, 2016 Category: Cancer & Oncology Authors: Anna Azvolinsky Tags: Brain Tumors News Pediatric Cancers Source Type: news

[Report] Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Cancers often evade immune surveillance by adopting peripheral tissue– tolerance mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the inhibition of which results in potent antitumor immunity. Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kinase that is highly active in postmitotic neurons and in many cancers, allows medulloblastoma (MB) to evade immune elimination. Interferon-γ (IFN-γ)–induced PD-L1 up-regulation on MB requires Cdk5, and disruption of Cdk5 expression in a mouse model of MB results in potent CD4+ T cell–mediated tumor rejec...
Source: ScienceNOW - July 21, 2016 Category: Science Authors: R. Dixon Dorand Source Type: news

In The Loop: Biology Professor Has Helping Others Down to a Science
This story originally appeared on the In the Loop blog. ____________________ In the summer of 2013, Anika Geibel was diagnosed with medulloblastoma, a type of brain tumor. She was just 7 1/2 years old. The diagnosis turned her life — and the lives of her family members — upside down. "We had been medically evacuated from Africa (where [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 4, 2016 Category: Databases & Libraries Source Type: news

Scientists uncover novel therapeutic targets and candidate biomarkers in childhood cancers
(Write Science Right) Brazilian scientists have obtained evidence suggesting that neurotrophins, which are well-known signaling molecules in normal brain development and function, may be useful biomarkers and therapeutic targets in childhood cancers. Blockade of the receptors that mediate neurotrophin signaling, namely TrkA and TrkB, have been shown to produce anticancer effects in both Ewing sarcoma and medulloblastoma. Additionally, levels of a neurotrophin have been associated with leukemia prognosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2016 Category: Cancer & Oncology Source Type: news

Oncurious begins Phase I/IIa study of TB-403 to treat medulloblastoma
Oncurious, along with BioInvent International and Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), has begun a Phase I/IIa study to evaluate the safety, tolerability and preliminary efficacy of TB-403 for the treatment of … (Source: Drug Development Technology)
Source: Drug Development Technology - May 2, 2016 Category: Pharmaceuticals Source Type: news

Adaptive Therapy May Help Kids Cope With Cancer
BOSTON (CBS) — Salma Costa, now five years old, had surgery, nine months of chemotherapy and then radiation which knocked her off her feet. The young girl suffers from medulloblastoma, an aggressive form of brain cancer. Fabiana Costa, Salma’s mom says, “She was very nauseaou. She would be vomiting all day. She didn’t want to play or do anything. She just wanted to lay down.” Despite aggressive treatment for , her tumor came back and doctors referred her to palliative care. But her mom was afraid to give up. “I called her doctor and I begged her to help us out with any trial treatments...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 18, 2016 Category: Consumer Health News Authors: mouellette2015 Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Watch Listen Cancer Dr. Mallika Marshall Source Type: news

BioInvent, Oncurious and US research consortium collaborate on TB-403 Phase I/IIa cancer trial
BioInvent International (BINV) and Oncurious have collaborated with the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) to accelerate a Phase I/IIa trial of TB-403. (Source: Drug Development Technology)
Source: Drug Development Technology - March 16, 2016 Category: Pharmaceuticals Source Type: news

New drug combination shows promise against childhood brain cancer
(Sanford-Burnham Prebys Medical Discovery Institute) Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new combination therapy for the most aggressive form of medulloblastoma, a fast growing pediatric brain cancer. In a study published online today in Cancer Cell, they show that panobinostat, an HDAC inhibitor, combined with a PI3K inhibitor, significantly slows growth of MYC-driven medulloblastomas. These results are expected to lead to a clinical trial to confirm the benefits of the novel drug combination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2016 Category: Cancer & Oncology Source Type: news

Hertfordshire woman told she could be pregnant learns she has BRAIN CANCER
Christine Tang, now 26, of Hemel Hempstead, Hertfordshire, was diagnosed with stage 4 medulloblastoma, a form of brain tumour rarely seen in adults. (Source: the Mail online | Health)
Source: the Mail online | Health - February 16, 2016 Category: Consumer Health News Source Type: news

Favourable safety, disease control for proton radiotherapy in paediatric medulloblastoma
Proton radiotherapy has an acceptable safety and disease control profile in paediatric medulloblastoma patients, according to research published in The Lancet Oncology. (Source: MedWire News)
Source: MedWire News - February 11, 2016 Category: Consumer Health News Tags: Neuro-oncology Source Type: news

Proton Beam in Medulloblastoma: 'New Benchmark'Proton Beam in Medulloblastoma: 'New Benchmark'
In children with medulloblastoma, proton-beam therapy has survival rates similar to standard radiotherapy, but fewer systemic toxicities. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 4, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Proton beam therapy reduces toxicity in treatment of pediatric medulloblastoma
Proton radiotherapy appeared as effective as but less toxic than conventional photon radiotherapy for the treatment of children with medulloblastoma, according to the results of an open-label phase 2 study published in Lancet Oncology. Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 4, 2016 Category: Endocrinology Source Type: news

Proton beam therapy 'effective' and 'causes fewer side effects'
ConclusionThis phase II study looked at the long-term side effects of using proton radiotherapy as part of the treatment of children with medulloblastoma. The treatment was used alongside standard surgical removal and chemotherapy. The current study is reported to be the longest prospective follow-up study available on this treatment for medulloblastoma.Overall, 12% of the study's participants had severe hearing loss three years after proton radiotherapy, and 16% at five years. This was reported by the authors to be less than the equivalent 23 Gy dose of standard (photon) radiotherapy, which was said to cause hearing loss ...
Source: NHS News Feed - February 1, 2016 Category: Consumer Health News Tags: Cancer Medical practice Source Type: news

Medical News Today: Proton therapy for cancer 'just as effective and safer' than standard radiotherapy
A trial finds a type of radiotherapy that uses protons instead of photons or X-rays is as effective at treating medulloblastoma in children and causes fewer long-term side effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 1, 2016 Category: Consumer Health News Tags: Radiology / Nuclear Medicine Source Type: news

Proton beam therapy offers potential to treat childhood brain cancer with fewer severe side effects than conventional radiotherapy
Proton beam therapy -- a more precise form of radiotherapy -- to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research. Importantly, the findings suggest that proton radiotherapy may not be as toxic to the rest of a child's body as conventional radiotherapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 30, 2016 Category: Science Source Type: news

The Lancet Oncology: Proton beam therapy offers potential to treat childhood brain cancer with fewer severe side effects than conventional radiotherapy
(The Lancet) Proton beam therapy -- a more precise form of radiotherapy -- to treat the childhood brain cancer medulloblastoma appears to be as safe as conventional radiotherapy with similar survival rates, according to new research published in The Lancet Oncology journal today. Importantly, the findings suggest that proton radiotherapy may not be as toxic to the rest of a child's body as conventional radiotherapy. The study was led by Dr. Torunn Yock, Massachusetts General Hospital, Proton Center, Boston, Mass., USA, and colleagues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2016 Category: Global & Universal Source Type: news

Proton Therapy Controls Common Pediatric Brain Tumor with Fewer Long-Term Side Effects (Massachusetts General Hospital Cancer Center)
The use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology. The paper from a team led by Massachusetts General Hospital (MGH) investigators describes patient outcomes an average of seven years after proton therapy for medulloblastoma, a fast-growing ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - January 29, 2016 Category: Cancer & Oncology Source Type: news

Researchers mine the epigenome to identify likely origins of childhood brain tumor subtype
(St. Jude Children's Research Hospital) An international research team led by a St. Jude Children's Research Hospital scientist mined the epigenome to discover the likely cell of origin for Group 4 medulloblastoma, a key step in developing targeted therapies (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 27, 2016 Category: Biology Source Type: news

Scientists identify protein interaction that defines an aggressive brain tumor subtype
Researchers show how the interaction of two proteins leads to medulloblastoma subtype with the worst prognosis. They also report that they have discovered a possible treatment strategy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 11, 2016 Category: Science Source Type: news

Scientists identify protein interaction that defines an aggressive brain tumor subtype
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital and University of Würzburg show how the interaction of two proteins leads to medulloblastoma subtype with the worst prognosis; scientists also discover possible treatment strategy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2016 Category: Global & Universal Source Type: news

[Editors' Choice] Channeling brain cancer
Drug development based on the antipsychotic drug thioridazine may lead to treatments for metastatic medulloblastoma without compromising quality of life. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 1, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news

Father with brain tumour is given just weeks to live
Alex Lewis Mayhew, 40, of Ibstock, Leicestershire, has been diagnosed with medulloblastoma, a brain tumour commonly found in children and has been told he will not live longer than a month. (Source: the Mail online | Health)
Source: the Mail online | Health - August 24, 2015 Category: Consumer Health News Source Type: news

Pediatric brain tumors can be classified noninvasively at diagnosis
Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups -- each with a different risk profile requiring subgroup-specific therapy. Investigators have now discovered that these subgroups can be determined non-invasively, using magnetic resonance spectroscopy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 7, 2015 Category: Science Source Type: news

Pediatric brain tumors can be classified noninvasively at diagnosis
(Children's Hospital Los Angeles) Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups -- each with a different risk profile requiring subgroup-specific therapy. Investigators at Children's Hospital Los Angeles have now discovered that these subgroups can be determined non-invasively, using magnetic resonance spectroscopy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 7, 2015 Category: Global & Universal Source Type: news

Targeted therapy shows effectiveness against a subtype of the brain tumor medulloblastoma
A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib, researchers report after a trial with both adults and children. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 30, 2015 Category: Science Source Type: news

Targeted therapy shows effectiveness against a subtype of the brain tumor medulloblastoma
(St. Jude Children's Research Hospital) A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib; St. Jude Children's Hospital led the Pediatric Brain Tumor Consortium trials in children and adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 29, 2015 Category: Global & Universal Source Type: news

Targeted Therapy Shows Effectiveness against a Subtype of the Brain Tumor Medulloblastoma
A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children's Research Hospital. St. Jude Children's Research Hospital/University of Tennessee Health Science Center is one of the 26 NCCN Member Institutions. ... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - July 29, 2015 Category: Cancer & Oncology Source Type: news

New drug for neuroblastoma shows promise in phase I study
(Spectrum Health) Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, M.D., and the Neuroblastoma and Medulloblastoma Translational Research Consortium, DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients. This is the first clinical study of an oral dosing form of DFMO in any pediatric population. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 1, 2015 Category: Biology Source Type: news

TGen, Dell expand pediatric cancer fight to Europe and Middle East
(The Translational Genomics Research Institute) Dell today announced its extended partnership with the Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world's first FDA-approved precision medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support the Neuroblastoma and Medulloblastoma Translational Research Consortium's expanded pediatric cancer clinical trials in EMEA, starting with sites in France and Lebanon. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 11, 2015 Category: Cancer & Oncology Source Type: news

Tracking defects caused by brain tumor mutation yields insight to advance targeted therapy
Scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor. The findings involve the DDX3X gene. In 2012, other work highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma. Such treatments target the genetic mistakes that give rise to the brain tumor’s four subtypes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 8, 2015 Category: Science Source Type: news